<p>Mersana Therapeutics（納斯達克代碼：MRSN - 獲取免費報告）在週四的報告中被 Lifesci Capital 的研究分析師從 “強力買入” 評級下調至 “持有” 評級，Zacks.com 報道。</p>
<p>其他股票研究分析師最近也對該股票發佈了報告。Guggenheim 在週五的報告中重新發布了對 Mersana Therapeutics 股票的 “中性” 評級。BTIG Research 在週四將 Mersana Therapeutics 的股票評級從 “買入” 下調至 “持有”。Truist Financial 在週四將 Mersana Therapeutics 的股票評級從 “買入” 下調至 “持有”，並將該公司的目標股價從 36.00 美元下調至 30.75 美元。Wedbush 在週四的研究報告中將 Mersana Therapeutics 的股票評級從 “強力買入” 下調至 “持有”。最後，William Blair 在週四的報告中將 Mersana Therapeutics 的股票評級從 “強力買入” 下調至 “市場表現”。七位分析師對該股票給予了 “持有” 評級，一位分析師對該公司給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “減持”，平均目標股價為 38.19 美元。</p>
<p>獲取 <strong>Mersana Therapeutics</strong> 的提醒：</p>
<p><strong>查看我們對 Mersana Therapeutics 的最新股票分析</strong></p>
<h2>Mersana Therapeutics 價格表現</h2>
<p>在週四的交易中，納斯達克代碼：MRSN 的股票上漲了 0.49 美元，達到 27.92 美元。該公司交易了 419,769 股，相較於其平均交易量 194,946 股。Mersana Therapeutics 的 52 周低點為 5.21 美元，52 周高點為 70.73 美元。該股票的 50 日移動平均線為 9.34 美元，200 日移動平均線為 8.63 美元。該公司的市值為 1.3935 億美元，市盈率為-1.91，貝塔值為 0.92。</p>
<p>Mersana Therapeutics（納斯達克代碼：MRSN - 獲取免費報告）最後一次發佈季度財報是在 11 月 14 日（週五）。該公司報告的每股收益（EPS）為-1.51 美元，低於分析師的共識預期-1.44 美元，差額為 0.07 美元。該公司在本季度的收入為 1101 萬美元，而共識預期為 1420 萬美元。賣方分析師預測 Mersana Therapeutics 在當前財政年度將發佈-0.62 美元的每股收益。</p>
<h2>Mersana Therapeutics 的機構交易</h2>
<p>一些對沖基金最近對其在 MRSN 的持倉進行了調整。摩根大通在第二季度將其在 Mersana Therapeutics 的持倉增加了 156.6%。摩根大通現在擁有 130,094 股該公司的股票，價值 39,000 美元，此前在上個季度增持了 79,390 股。Invesco Ltd.在第一季度將其在 Mersana Therapeutics 的持倉增加了 109.3%。Invesco Ltd.現在擁有 114,863 股該公司的股票，價值 40,000 美元，此前在上個季度增持了 59,991 股。Algert Global LLC 在第一季度將其在 Mersana Therapeutics 的持倉增加了 124.7%。Algert Global LLC 現在擁有 135,013 股該公司的股票，價值 46,000 美元，此前在上個季度增持了 74,930 股。CWM LLC 在第一季度將其在 Mersana Therapeutics 的持倉增加了 102,580.6%。CWM LLC 現在擁有 184,825 股該公司的股票，價值 64,000 美元，此前在上個季度增持了 184,645 股。最後，Marshall Wace LLP 在第二季度購買了 Mersana Therapeutics 的股票，價值約 68,000 美元。93.92% 的股票由機構投資者持有。</p>
<h2>Mersana Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Mersana Therapeutics, Inc 是一家臨牀階段的生物製藥公司，開發針對有未滿足需求的癌症患者的抗體藥物偶聯物（ADC）。該公司開發了 XMT-1660，一種針對 B7-H4 的 Dolasynthen ADC 候選藥物；以及 XMT-2056，一種免疫合成 ADC。它與 Janssen Biotech, Inc、Ares Trading SA、默克 KGaA 和 Asana BioSciences, LLC 進行 ADC 產品候選藥物的研發合作。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Mersana Therapeutics 更好</li>
<li>什麼是稀釋每股收益（Diluted EPS）？</li>
<li>你的感恩節投資計劃：3 只受益於足球熱潮的股票</li>
<li>如何在購買前評估一隻股票</li>
<li>MarketBeat 週迴顧 – 11/10 - 11/14</li>
<li>什麼是便士股票？全面指南</li>
<li>這三隻被低估的科技巨頭準備反彈嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJTTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJTTg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Mersana Therapeutics 嗎？</h2>
<p>在你考慮 Mersana Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意之前立即購買……而 Mersana Therapeutics 並不在名單上。</p>
<p>雖然 Mersana Therapeutics 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MRSN

<p>Lifesci Capital 將 Mersana Therapeutics（NASDAQ:MRSN）的評級從 “強力買入” 下調至 “持有”。其他分析師，包括 Guggenheim、BTIG Research、Truist Financial、Wedbush 和 William Blair，也下調了該股票的評級。該股票的平均評級為 “減持”，目標價格為 38.19 美元。Mersana 的股價上漲至 27.92 美元，市值為 1.3935 億美元。該公司報告了季度虧損，未能達到預期。機構投資者持有 93.92% 的股份。Mersana 開發用於癌症治療的抗體藥物偶聯物（ADCs），並與多家生物科技公司合作</p>

<p>Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) was downgraded by research analysts at Lifesci Capital from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report issued on Thursday,Zacks.com reports.</p>
<div class="lb-trans"><p>Mersana Therapeutics（納斯達克代碼：MRSN - 獲取免費報告）在週四的報告中被 Lifesci Capital 的研究分析師從 “強力買入” 評級下調至 “持有” 評級，Zacks.com 報道。</p>
</div><p>Other equities research analysts also recently issued reports about the stock. Guggenheim reissued a &#34;neutral&#34; rating on shares of Mersana Therapeutics in a report on Friday. BTIG Research lowered shares of Mersana Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday. Truist Financial downgraded shares of Mersana Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating and cut their price target for the company from $36.00 to $30.75 in a report on Thursday. Wedbush lowered shares of Mersana Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday. Finally, William Blair cut shares of Mersana Therapeutics from a &#34;strong-buy&#34; rating to a &#34;market perform&#34; rating in a report on Thursday. Seven analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Reduce&#34; and an average price target of $38.19.</p>
<div class="lb-trans"><p>其他股票研究分析師最近也對該股票發佈了報告。Guggenheim 在週五的報告中重新發布了對 Mersana Therapeutics 股票的 “中性” 評級。BTIG Research 在週四將 Mersana Therapeutics 的股票評級從 “買入” 下調至 “持有”。Truist Financial 在週四將 Mersana Therapeutics 的股票評級從 “買入” 下調至 “持有”，並將該公司的目標股價從 36.00 美元下調至 30.75 美元。Wedbush 在週四的研究報告中將 Mersana Therapeutics 的股票評級從 “強力買入” 下調至 “持有”。最後，William Blair 在週四的報告中將 Mersana Therapeutics 的股票評級從 “強力買入” 下調至 “市場表現”。七位分析師對該股票給予了 “持有” 評級，一位分析師對該公司給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “減持”，平均目標股價為 38.19 美元。</p>
</div><p>Get <strong>Mersana Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Mersana Therapeutics</strong> 的提醒：</p>
</div><p><strong>View Our Latest Stock Analysis on Mersana Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Mersana Therapeutics 的最新股票分析</strong></p>
</div><h2>Mersana Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Mersana Therapeutics 價格表現</h2>
</div><p>Shares of NASDAQ:MRSN traded up $0.49 during trading on Thursday, hitting $27.92. 419,769 shares of the company were exchanged, compared to its average volume of 194,946. Mersana Therapeutics has a 52-week low of $5.21 and a 52-week high of $70.73. The stock has a 50 day moving average of $9.34 and a 200 day moving average of $8.63. The company has a market cap of $139.35 million, a PE ratio of -1.91 and a beta of 0.92.</p>
<div class="lb-trans"><p>在週四的交易中，納斯達克代碼：MRSN 的股票上漲了 0.49 美元，達到 27.92 美元。該公司交易了 419,769 股，相較於其平均交易量 194,946 股。Mersana Therapeutics 的 52 周低點為 5.21 美元，52 周高點為 70.73 美元。該股票的 50 日移動平均線為 9.34 美元，200 日移動平均線為 8.63 美元。該公司的市值為 1.3935 億美元，市盈率為-1.91，貝塔值為 0.92。</p>
</div><p>Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last released its quarterly earnings data on Friday, November 14th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.44) by ($0.07). The company had revenue of $11.01 million during the quarter, compared to the consensus estimate of $14.20 million. Sell-side analysts forecast that Mersana Therapeutics will post -0.62 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Mersana Therapeutics（納斯達克代碼：MRSN - 獲取免費報告）最後一次發佈季度財報是在 11 月 14 日（週五）。該公司報告的每股收益（EPS）為-1.51 美元，低於分析師的共識預期-1.44 美元，差額為 0.07 美元。該公司在本季度的收入為 1101 萬美元，而共識預期為 1420 萬美元。賣方分析師預測 Mersana Therapeutics 在當前財政年度將發佈-0.62 美元的每股收益。</p>
</div><h2>Institutional Trading of Mersana Therapeutics</h2>
<div class="lb-trans"><h2>Mersana Therapeutics 的機構交易</h2>
</div><p>A number of hedge funds have recently made changes to their positions in MRSN. JPMorgan Chase &amp; Co. grew its position in Mersana Therapeutics by 156.6% in the second quarter. JPMorgan Chase &amp; Co. now owns 130,094 shares of the company's stock worth $39,000 after acquiring an additional 79,390 shares in the last quarter. Invesco Ltd. lifted its stake in Mersana Therapeutics by 109.3% during the first quarter. Invesco Ltd. now owns 114,863 shares of the company's stock worth $40,000 after purchasing an additional 59,991 shares during the last quarter. Algert Global LLC boosted its holdings in shares of Mersana Therapeutics by 124.7% in the 1st quarter. Algert Global LLC now owns 135,013 shares of the company's stock worth $46,000 after purchasing an additional 74,930 shares in the last quarter. CWM LLC boosted its holdings in shares of Mersana Therapeutics by 102,580.6% in the 1st quarter. CWM LLC now owns 184,825 shares of the company's stock worth $64,000 after purchasing an additional 184,645 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Mersana Therapeutics during the 2nd quarter valued at about $68,000. 93.92% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金最近對其在 MRSN 的持倉進行了調整。摩根大通在第二季度將其在 Mersana Therapeutics 的持倉增加了 156.6%。摩根大通現在擁有 130,094 股該公司的股票，價值 39,000 美元，此前在上個季度增持了 79,390 股。Invesco Ltd.在第一季度將其在 Mersana Therapeutics 的持倉增加了 109.3%。Invesco Ltd.現在擁有 114,863 股該公司的股票，價值 40,000 美元，此前在上個季度增持了 59,991 股。Algert Global LLC 在第一季度將其在 Mersana Therapeutics 的持倉增加了 124.7%。Algert Global LLC 現在擁有 135,013 股該公司的股票，價值 46,000 美元，此前在上個季度增持了 74,930 股。CWM LLC 在第一季度將其在 Mersana Therapeutics 的持倉增加了 102,580.6%。CWM LLC 現在擁有 184,825 股該公司的股票，價值 64,000 美元，此前在上個季度增持了 184,645 股。最後，Marshall Wace LLP 在第二季度購買了 Mersana Therapeutics 的股票，價值約 68,000 美元。93.92% 的股票由機構投資者持有。</p>
</div><h2>Mersana Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Mersana Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.</p>
<div class="lb-trans"><p>Mersana Therapeutics, Inc 是一家臨牀階段的生物製藥公司，開發針對有未滿足需求的癌症患者的抗體藥物偶聯物（ADC）。該公司開發了 XMT-1660，一種針對 B7-H4 的 Dolasynthen ADC 候選藥物；以及 XMT-2056，一種免疫合成 ADC。它與 Janssen Biotech, Inc、Ares Trading SA、默克 KGaA 和 Asana BioSciences, LLC 進行 ADC 產品候選藥物的研發合作。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Mersana Therapeutics</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>MarketBeat Week in Review – 11/10 - 11/14</li>
<li>What is a penny stock? A comprehensive guide</li>
<li>Are These 3 Oversold Tech Giants Ready to Rebound?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Mersana Therapeutics 更好</li>
<li>什麼是稀釋每股收益（Diluted EPS）？</li>
<li>你的感恩節投資計劃：3 只受益於足球熱潮的股票</li>
<li>如何在購買前評估一隻股票</li>
<li>MarketBeat 週迴顧 – 11/10 - 11/14</li>
<li>什麼是便士股票？全面指南</li>
<li>這三隻被低估的科技巨頭準備反彈嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJTTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MRSN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Mersana Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Mersana Therapeutics 嗎？</h2>
</div><p>Before you consider Mersana Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Mersana Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mersana Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意之前立即購買……而 Mersana Therapeutics 並不在名單上。</p>
</div><p>While Mersana Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Mersana Therapeutics 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Lifesci Capital 將 Mersana Therapeutics（NASDAQ:MRSN）的評級下調為持有